CommuniTake Remote Support Platform Delivers Clientless Remote iPhone Configuration
The new remote iPhone configuration helps boost support productivity and efficiency to reduce time and resources required to complete on-iPhone device deployments
CommuniTake Technologies has announced today that its Remote Support application is now providing clientless remote configuration for iPhone and iPad devices. Building on CommuniTake's commitment to simplify the support of Smartphones, the remote iPhone and iPad configuration radically changes iOS device support processes. The new solution provides support representatives with the ability to remotely define complex iOS device settings such as Email (POP3/IMAP & SMTP), Exchange Server, APN configurations and Wi-Fi.
Clientless remote iPhone configuration delivers customer value
CommuniTake's new solution provides greater flexibility in serving customers and drives increased support productivity through improved support representative practices: the support representative fills in the required profile fields and sends an SMS to the target iPhone. The new profile is automatically downloaded to the iPhone once the device holder opens the embedded link via secure access. Multiple configurations can be defined through one profile and the support representative can select a procedure from an extensive definitions library.
The new solution provides comprehensive and efficient device management processes that successfully provision and manage device utilization. Being a clientless solution, it enables rapid time-to-market across support operations.
The solution streamlines the changing needs of support representatives, allows higher customer satisfaction and reduces the needs of customers to reach points of service.
Supporting quotes
"We are focused on optimizing customer service and operational efficiency at the multi-channel support level. The clientless remote iPhone configuration extends our market-leading product’s capabilities," says Ronen Sasson, CommuniTake Technologies CEO.
"With this capability, service providers can capitalize on the operational advantages of running a remote support instance across their customer touch points. The user-friendly, Web-based application also enables enterprise IT personnel, in any location, to maintain, update and change devices logic without the need for external support professionals. It significantly intensifies the use of the enterprise devices across the daily tasks of enterprise professionals."
About CommuniTake Technologies Ltd.
CommuniTake Technologies was formed in 2009 and is privately held. The company is currently running several pilots with European tier 1 operators, a leading solution implementer and a prominent device manufacturer. CommuniTake Technologies has also sold its remote support platform to major operators and corporations in Israel. CommuniTake is the world's first to pre-install remote support on commercial AndroidTM devices and the world's best in market coverage across mobile OSs and devices. Recently, CommuniTake won RIM's 2010 EMEA innovation award for service excellence and it was selected by SFR (France) to be part of its prestigious young talent start-ups program. For additional information please visit the company's website www.communitake.com .
Trademarks
iPhone and iPad are trademarks of Apple Inc., registered in the U.S. and other countries.
Android is a trademark of Google Inc. Use of this trademark is subject to Google Permissions.
Contact:
CommuniTake Technologies Ltd.
Noam Potter, +972.545.515516
noam@communitake.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release
Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release
IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release
Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom